BCD 225
Alternative Names: BCD-225Latest Information Update: 08 Jun 2022
At a glance
- Originator Biocad
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2022 Preclinical trials in Solid tumours in Russia (Parenteral) Before May 2022 (Biocad pipeline, May 2022)